Merrimack lung cancer drug fails goal in one mid-stage trial group
April 4 (Reuters) - Merrimack Pharmaceuticals Inc said one of three patient groups in a mid-stage trial of its experimental lung cancer drug failed to meet the main goal of improving survival rates after four months of treatment without the disease worsening.
The group was administered the drug, MM-121, in combination with erlotinib, an approved cancer treatment, for non-small cell lung cancer.
The main goal was to show a 40 percent improvement in progression-free survival after four months.
The drug is also being evaluated in two other lung-cancer patient groups, and in separate studies for ovarian and breast cancer.
- Malaysian plane presumed crashed; questions over false IDs |
- China draws 'red line' on North Korea, says won't allow war on peninsula
- Warning shots fired to turn monitors back from Crimea |
- Malaysian plane crashed off Vietnam coast: state media